Managing aromatase inhibitor-associated bone loss in breast cancer

Allan Lipton, Michael Gnant, Matti Aapro

Research output: Contribution to journalReview article

2 Citations (Scopus)

Abstract

Although the incidence of breast cancer has increased, there is a concurrent decrease in the death rate, and the outlook for women with early-stage breast cancer remains positive. The current 5-year survival rate of women diagnosed with breast cancer is nearly 90%, due, in part, to the use of effective adjuvant therapies that often include aromatase inhibitors. However, long-term treatment with these therapies is known to have adverse effects on bone metabolism, leading to bone loss. Bone loss during adjuvant endocrine therapy may be higher than that observed during menopause and may require more potent therapy. Although there are approved treatments for osteolytic bone lesions from bone metastases, there is no approved therapy for bone loss associated with adjuvant cancer therapy. Bisphosphonates have demonstrated promising results in this setting, and zoledronic acid is currently under consideration by the US FDA and Europe (EMEA) for the treatment of aromatase inhibitor-associated bone loss.

Original languageEnglish (US)
Pages (from-to)441-448
Number of pages8
JournalWomen's Health
Volume3
Issue number4
DOIs
StatePublished - Jul 1 2007

Fingerprint

Aromatase Inhibitors
Breast Neoplasms
Bone and Bones
Therapeutics
zoledronic acid
Diphosphonates
Menopause
Survival Rate
Neoplasm Metastasis
Mortality
Incidence

All Science Journal Classification (ASJC) codes

  • Medicine(all)

Cite this

Lipton, Allan ; Gnant, Michael ; Aapro, Matti. / Managing aromatase inhibitor-associated bone loss in breast cancer. In: Women's Health. 2007 ; Vol. 3, No. 4. pp. 441-448.
@article{1359445e14f24e8db068279f9eba37a6,
title = "Managing aromatase inhibitor-associated bone loss in breast cancer",
abstract = "Although the incidence of breast cancer has increased, there is a concurrent decrease in the death rate, and the outlook for women with early-stage breast cancer remains positive. The current 5-year survival rate of women diagnosed with breast cancer is nearly 90{\%}, due, in part, to the use of effective adjuvant therapies that often include aromatase inhibitors. However, long-term treatment with these therapies is known to have adverse effects on bone metabolism, leading to bone loss. Bone loss during adjuvant endocrine therapy may be higher than that observed during menopause and may require more potent therapy. Although there are approved treatments for osteolytic bone lesions from bone metastases, there is no approved therapy for bone loss associated with adjuvant cancer therapy. Bisphosphonates have demonstrated promising results in this setting, and zoledronic acid is currently under consideration by the US FDA and Europe (EMEA) for the treatment of aromatase inhibitor-associated bone loss.",
author = "Allan Lipton and Michael Gnant and Matti Aapro",
year = "2007",
month = "7",
day = "1",
doi = "10.2217/17455057.3.4.441",
language = "English (US)",
volume = "3",
pages = "441--448",
journal = "Women's Health",
issn = "1745-5057",
number = "4",

}

Managing aromatase inhibitor-associated bone loss in breast cancer. / Lipton, Allan; Gnant, Michael; Aapro, Matti.

In: Women's Health, Vol. 3, No. 4, 01.07.2007, p. 441-448.

Research output: Contribution to journalReview article

TY - JOUR

T1 - Managing aromatase inhibitor-associated bone loss in breast cancer

AU - Lipton, Allan

AU - Gnant, Michael

AU - Aapro, Matti

PY - 2007/7/1

Y1 - 2007/7/1

N2 - Although the incidence of breast cancer has increased, there is a concurrent decrease in the death rate, and the outlook for women with early-stage breast cancer remains positive. The current 5-year survival rate of women diagnosed with breast cancer is nearly 90%, due, in part, to the use of effective adjuvant therapies that often include aromatase inhibitors. However, long-term treatment with these therapies is known to have adverse effects on bone metabolism, leading to bone loss. Bone loss during adjuvant endocrine therapy may be higher than that observed during menopause and may require more potent therapy. Although there are approved treatments for osteolytic bone lesions from bone metastases, there is no approved therapy for bone loss associated with adjuvant cancer therapy. Bisphosphonates have demonstrated promising results in this setting, and zoledronic acid is currently under consideration by the US FDA and Europe (EMEA) for the treatment of aromatase inhibitor-associated bone loss.

AB - Although the incidence of breast cancer has increased, there is a concurrent decrease in the death rate, and the outlook for women with early-stage breast cancer remains positive. The current 5-year survival rate of women diagnosed with breast cancer is nearly 90%, due, in part, to the use of effective adjuvant therapies that often include aromatase inhibitors. However, long-term treatment with these therapies is known to have adverse effects on bone metabolism, leading to bone loss. Bone loss during adjuvant endocrine therapy may be higher than that observed during menopause and may require more potent therapy. Although there are approved treatments for osteolytic bone lesions from bone metastases, there is no approved therapy for bone loss associated with adjuvant cancer therapy. Bisphosphonates have demonstrated promising results in this setting, and zoledronic acid is currently under consideration by the US FDA and Europe (EMEA) for the treatment of aromatase inhibitor-associated bone loss.

UR - http://www.scopus.com/inward/record.url?scp=34447578662&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34447578662&partnerID=8YFLogxK

U2 - 10.2217/17455057.3.4.441

DO - 10.2217/17455057.3.4.441

M3 - Review article

C2 - 19804020

AN - SCOPUS:34447578662

VL - 3

SP - 441

EP - 448

JO - Women's Health

JF - Women's Health

SN - 1745-5057

IS - 4

ER -